NASDAQ •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 07/24/2026
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1.71 mln
Float0.58 mln
Earnings Date08/13/2026
EPS
0.10
Marginal
P / E
28.90
Elevated
Piotroski F-Score
3
/ 9
Below average
Relative Strength
54
/ 100
Slightly ahead
Debt / Equity
0.06
Debt-free
ROE
-390
Deeply negative
Business Description
Shuttle Pharmaceuticals Holdings Inc. is a clinical-stage company focused on discovering and developing new treatments for cancer. Founded in 2012 and based in Gaithersburg, Maryland, the company has several drug candidates in development targeting brain tumors, sarcomas, and breast cancer. Its lead product, Ropidoxuridine, is taken by mouth and is currently being tested in patients, while additional compounds in earlier stages of research aim to work through the body's immune system and other biological pathways involved in cancer growth.
